Last checked at 28 Nov 2014 07:00
Proteome Sciences plc
("Proteome" or the "Company")
SysQuant® - Update/Contract Awards
28 November, 2014: The board is pleased to announce that the further assessment of an additional 20 cases of pancreatic cancer using SysQuant® has recently been completed. The results validate the findings from the first 12 cases that were published earlier this year in PLOS ONE. As well as potential new drug targets, a key outcome of this study is a set of new biomarkers predicting the likelihood and timescale of tumour recurrence after surgery and the ability to match patients to individual drug treatments. Proteome has already filed patent applications around these markers.
The recent integration of the Orbitrap fusion mass spectrometer with our new IT installation has resulted in a 4x increase in protein detection in less than quarter of the time taken compared to the original study.
The application of SysQuant® in neurodegeneration has also been expanded through collaboration with a leading academic group to study the changes in cell signalling related to tau pathology in Alzheimer's disease. As with the pancreatic cancer study this is expected to identify novel biomarkers and new drug targets. We expect publication of these results in 2015.
In a separate study the Company is combining SysQuant® with its patented TMT®calibrator workflow to enhance discovery of biomarkers for Alzheimer's disease. A preliminary study has just been completed which has identified more than 100 additional brain proteins that may serve as biomarkers in cerebrospinal fluid. Translation of these into blood is now anticipated in 2015.
SysQuant® is attracting strong interest from pharmaceutical companies and we are pleased to confirm that it has been awarded two contracts in the last fortnight, including proof of concept studies, with further contracts in negotiation.
- Ends -
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Executive Chairman | |
Dr. Ian Pike, Chief Operating Officer | Tel: +44 (0)1932 865065 |
Geoff Ellis, Finance Director | |
Nominated Adviser | |
Cenkos | |
Mark Connelly/Callum Davidson finnCap Geoff Nash | Tel: +44 (0)20 7397 8900
Tel : +44 (0)20 7220 0563 |
Public Relations | |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
Mobile +44(0)7979 900733 | |
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.